Eterna Therapeutics Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ERNA, updated each market day.
ERNA AI Sentiment
AI predicts Eterna Therapeutics Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Eterna Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Sector
Exchange
Market Cap
$6,008,728
Cap Tier
Employees
5
Headquarters
CAMBRIDGE, MA
Listed Since
March 26, 2021
Website
ERNA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ERNA Volatility
Eterna Therapeutics Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
